Medtech Start-Ups Face Funding Challenges Ahead
The worldwide recession, uncertainty over US health care reform, and coming changes in the regulatory environment have conspired to limit funding for medical device start-up companies. Investor enthusiasm has been driven down and venture capital markets, which have historically served as the lifeblood of medical device innovation, have been deeply cut, with signs of further contraction as some VCs close their doors. The sector finds itself in, at best, a holding pattern as executives scramble for new sources of operating cash. Medtech reports from the recent Advamed and IN3 conferences.
You may also be interested in...
Venture capitalists speaking at the Medtech Insight IN3 Medical Device Summit in San Francisco in October stressed that they need to know how much capital a company will need to break even or turn a profit.
The global recession that struck last September drove many device investors into hiding. This left a barren financial landscape for device companies to subsist on. But some are finding the funds they need, and they're sharing their survival stories.
The need for a positive economic argument when introducing a new medtech product is more critical than ever. Management teams are well aware of the need to demonstrate compelling economic data, but can a product still be successful without an economic benefit in the increasingly cost-conscious health care marketplace? Overcoming negative economics means identifying a combination of positive attributes that can overcome the economic barrier, and this thought process should be conducted well before significant R&D funds are invested.